Cullinan Management CGEM 深 沪
已收盘 10-31 16:00:00 美东时间
8.66
+1.100
+14.55%
华盛通- 最 高8.7796
- 今 开7.82
- 成交量 184.49万股
- 最 低 7.64
- 昨 收 7.56
- 总市值 5.12亿
- 52周最高 17.5034
- 市盈率 静 --
- 换手率 3.12%
- 52周最低 5.68
- 委 比 -75.79%
- 总股本 5907.44万
- 历史最高 59.85
- 量 比 2.22
- 振 幅 15.07%
- 历史最低 5.68
- 每 手 1
- 风险率 2.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
Cullinan Therapeutics presented new preclinical data on CLN-978, a CD19xCD3 bispecific T cell engager, at ACR Convergence 2025. The data demonstrated that CLN-978 rapidly and deeply depletes B cells in vitro and in vivo across multiple autoimmune diseases, including rheumatoid arthritis, Sjögren's disease, and systemic lupus erythematosus. Preclinical studies in nonhuman primates and murine models showed dose-dependent B cell depletion and diseas...
10-25 15:01
Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations
Zipalertinib shows 31% intracranial response and good tolerability in CNS-involved EGFR-mutated lung cancer, data presented at ESMO 2025.
10-14 00:46
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $24 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $24 price target.
09-12 18:37
Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
Cullinan Therapeutics announced that its Chief Medical Officer, Jeffrey Jones, M.D., M.B.A., will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 16, 2025. A webcast of the event will be available on the Company’s investor relations website. Cullinan is a biopharmaceutical company focused on developing targeted therapies for autoimmune diseases and cancer, with a diversified portfolio of cl...
09-12 11:00
Taiho Oncology And Cullinan Therapeutics Report 27% Response Rate In REZILIENT1 And 30% Response Rate In REZILIENT2 Lung Cancer Trial
Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., today announced new data from the REZILIENT1 and REZILIENT2 trials of zipalertinib, an oral EGFR tyrosine kinase inhibitor, in patients with advanced or metastatic
09-09 17:49
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) announced its participation in two upcoming investor conferences. CEO Nadim Ahmed and CMO Jeffrey Jones will attend the Cantor Global Healthcare Conference 2025 in New York on September 4, 2025, and the Morgan Stanley Global Healthcare Conference in New York on September 10, 2025. Webcasts of the fireside chats will be available on the company’s investor relations website. Cullinan, a biopharmaceutical c...
08-21 20:05
Morgan Stanley Maintains Overweight on Cullinan Therapeutics, Lowers Price Target to $28
Morgan Stanley analyst Jeffrey Hung maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Overweight and lowers the price target from $35 to $28.
08-18 21:12
Cullinan Therapeutics Q2 EPS $(1.07) Misses $(0.84) Estimate
Cullinan Therapeutics (NASDAQ:CGEM) reported quarterly losses of $(1.07) per share which missed the analyst consensus estimate of $(0.84) by 26.93 percent. This is a 57.35 percent decrease over losses of $(0.68) per
08-07 19:18
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
Cullinan Therapeutics reported updates on its CLN-978 program across three Phase 1 studies in systemic lupus erythematosus, rheumatoid arthritis, and Sjögren’s disease, and the in-licensing of velinotamig, a BCMA-directed bispecific T cell engager. The company also shared pivotal results for zipalertinib at ASCO 2025 and announced the appointment of Mittie Doyle and Andrew Allen to its Board of Directors. Financially, the company ended Q2 2025 wi...
08-07 11:00
